Hims Hers Health Inc (HIMS)
Official siteHEALTHCARE • HOUSEHOLD & PERSONAL PRODUCTS • NYSE
Market Cap: $4.62B
Last updated: Nov 17, 2026 at 11:06 AM ET
Hims Hers Health Inc (HIMS) Stock Forecast
Analysts expect Hims Hers Health (HIMS) to earn -$0.83 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.14B. Of 15 analysts, 3 rate the stock Buy or Strong Buy, 12 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.67, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 20% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 13.3% |
| Buy | 1 | 6.7% |
| Hold | 12 | 80.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 22.9%.
- Fiscal year ending Dec 31, 2026
- -$0.83
- EPS consensus, revenue $3.14B
- Fiscal year ending Dec 31, 2027
- $0.07
- EPS consensus, revenue $3.86B
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.83 | -$1.15 to -$0.46 | 11 | $3.14B | $3.13B to $3.18B | 13 |
| Dec 31, 2027 | $0.07 | -$0.37 to $0.45 | 11 | $3.86B | $3.68B to $4.37B | 14 |
Quarterly Estimates
The EPS consensus falls from $0.12 for the quarter ending Dec 31, 2026 to -$0.06 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.12 | -$0.02 to $0.33 | 15 | $924.38M | $863.38M to $1.10B | 14 |
| Mar 31, 2027 | -$0.06 | -$0.20 to $0.01 | 4 | $904.06M | $860.90M to $953.50M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.46.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.83 | -$0.56 | -$0.56 | -$0.56 | -$0.46 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.07 | $0.42 | $0.42 | $0.42 | $0.59 | -88.3% |
| Quarter ending Mar 31, 2027 | -$0.06 | $0.05 | $0.05 | $0.05 | $0.07 | N/A |
Frequently Asked Questions About HIMS
What is the HIMS stock forecast?
Consensus analyst estimates put Hims Hers Health's EPS at -$0.83 for the fiscal year ending Dec 31, 2026, on revenue of $3.14B. The consensus rating from 15 analysts is Hold.
How do analysts rate HIMS stock?
Of 15 analysts covering Hims Hers Health, 2 rate it Strong Buy, 1 Buy, 12 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from HIMS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.83, with estimates from -$1.15 to -$0.46 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.07, with estimates from -$0.37 to $0.45 from 11 analysts.
What revenue do analysts expect from Hims Hers Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.14B, with estimates from $3.13B to $3.18B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.86B, with estimates from $3.68B to $4.37B.
How many analysts cover HIMS?
15 analysts rate Hims Hers Health stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
HIMS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors